Abstract:Abstract Background Over 90% of children with reported penicillin allergy can tolerate penicillin without incident. Developing effective and safe strategies to remove inappropriate penicillin allergies has the potential to improve care; however, guidance on how to identify, test, and delabel patients is limited. Methods In April 2019, Children’s Hospital Colorado (CHCO) implemented a penicillin allergy clinical pathway (CP) alongside a risk assessment tool to stratify patients based on allergic history (Figure 1). Patients at “no increased risk” were educated and delabeled without testing. Low risk patients were offered an oral amoxicillin drug challenge with close observation. A single, non-graded, treatment dose of amoxicillin (45 mg/kg, max dose 1000mg) was used for low risk patients, and no preceding allergic skin testing was performed. Patients with no signs or symptoms of allergic response 60 minutes after amoxicillin administration were delabeled. Children delabeled of penicillin allergies on the CHCO hospital medicine service were compared between the pre-CP (1/1/17-3/31/19) and post-CP (4/1/19-3/31/20) cohorts. Figure 1. Penicillin Allergy Risk Assessment Results Pre-CP, 683/10624 (6.4%) patients reported a penicillin allergy and 18/683 (2.6%) were delabeled by discharge. Post-CP, 345/6559 (5.3%) patients reported a penicillin allergy and 47/345 (13.6%) were delabeled by discharge (P-value < 0.0001, Figure 2). Among the 47 post-CP patients, 11 were delabeled by history alone, 19 underwent oral amoxicillin drug challenge per CP, and 17 received a different treatment dose penicillin per treatment team. Only one penicillin-exposed patients had a reaction. This patient developed a delayed, non-progressive rash and had penicillin allergy restored to their chart. No patient required emergency medical intervention, and none were “relabeled” penicillin allergic in the 6 months following discharge. Figure 2. Monthly Rate of Penicillin Allergic Patients Delabeled by Discharge Conclusion A drug challenge using a single non-graded dose of oral amoxicillin is a safe and effective strategy to delabel low risk children of inappropriate penicillin allergies when implemented alongside a risk assessment tool. Further studies are needed to evaluate the long-term benefits of delabeling inappropriate penicillin allergies and to continue monitoring for adverse events. Disclosures All Authors: No reported disclosures

Allergy to beta-lactam antibiotics in children: predictors for a positive oral challenge test

Outpatient and primary care direct provocation challenges for antibiotic allergy in children

Comparing skin and serum testing to direct challenge outcomes in children with beta-lactam allergies

Improving inpatient paediatric de-labelling of allergies to beta-lactams: a quality improvement study

Direct oral provocation test with beta-lactams in Brazilian children and adolescents

1332. Single Dose Oral Amoxicillin Challenge is a Safe and Effective Strategy to Delabel Penicillin Allergies among Low Risk Hospitalized Children

Full‐dose challenge of moderate, severe, and unknown beta‐lactam allergies in the emergency department

Inpatient allergy delabeling of pediatric patients with low-risk penicillin allergy status through direct oral amoxicillin challenge

Direct Oral Challenge for Immediate and Non-Immediate β -Lactam Allergy in Children: A Real-World Multicenter Study

Beta‐lactam allergy risk stratification in a maternity population in Australia: Scope for allergy de‐labelling

Promoting penicillin allergy de‐labeling for children attending a hematology clinic

Introduction of a penicillin allergy de-labelling program with direct oral challenge and its effects on utilization of beta-lactam antimicrobials: a multicenter retrospective parallel cohort study

Comparative Performance of 4 Penicillin-Allergy Prediction Strategies in a Large Cohort

Early testing and grade of the reaction are affecting factors of skin test positivity in β-Lactam allergies

Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center

Delabelling beta-lactam allergy

567. The Quality & Management of Penicillin Allergy Labels in a Pediatric Birth Cohort

Antepartum vs postpartum amoxicillin oral challenge in pregnant patients with a reported penicillin allergy: A two-center prospective cohort study

Removing penicillin allergy label in a hospitalized adolescent with a remote penicillin and recent cephalosporin allergy

Incidence of amoxycillin-clavulanic acid associated hepatotoxicity in an Australian children’s hospital

Risk Stratification of Penicillin Allergy Labeled Children: A Cross-Sectional Study from Jordan